<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="408">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04313322</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19</org_study_id>
    <nct_id>NCT04313322</nct_id>
  </id_info>
  <brief_title>Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells</brief_title>
  <official_title>Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stem Cells Arabia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stem Cells Arabia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal
      stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2
      infection, and showing symptoms of COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a
      high transmission rate and is spreading at very high rates. causing a worldwide pandemic.
      Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three
      IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each
      other.

      Patients will be followed up for a period of three weeks to assess the severity of the
      condition and measure the viral titers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 16, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients positively diagnosed with COVID-19</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None. This is a direct study for the potential effects of WJ-MSCs on COVID-19 outcome.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcome</measure>
    <time_frame>3 weeks</time_frame>
    <description>Improvement of clinical symptoms including duration of fever, respiratory destress, pneumonia, cough, sneezing, diarrhea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CT Scan</measure>
    <time_frame>3 weeks</time_frame>
    <description>Side effects measured by Chest Readiograph</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RT-PCR results</measure>
    <time_frame>3 weeks</time_frame>
    <description>Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RT-PCR results</measure>
    <time_frame>8 weeks</time_frame>
    <description>Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negative</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Use of Stem Cells for COVID-19 Treatment</condition>
  <arm_group>
    <arm_group_label>WJ-MSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.
WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>WJ-MSCs</intervention_name>
    <description>WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.
WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.</description>
    <arm_group_label>WJ-MSCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.

        Exclusion Criteria:

          -  Participants in other clinical trials

          -  patients with malignant tumors

          -  pregnant and lactating women

          -  co-infection with other infectious viruses or bacteria

          -  History of several allergies

          -  Patients with history of pulmonary embolism

          -  any liver or kidney diseases

          -  HIV positive patients

          -  Considered by researchers to be not suitable to participate in this clinical trial

          -  Chronic heart failure with ejection fraction less than 30%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adeeb M AlZoubi, Ph.D.</last_name>
    <phone>+962795337575</phone>
    <email>adeebalzoubi@stemcellsarabia.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmad Y AlGhadi, M.Sc.</last_name>
    <phone>+962796624217</phone>
    <email>ahmed.alghadi@stemcellsarabia.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stem Cells Arabia</name>
      <address>
        <city>Amman</city>
        <zip>11953</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeeb M Alzoubi, Ph.D.</last_name>
      <phone>+962795337575</phone>
      <email>adeebalzoubi@stemcellsarabia.net</email>
    </contact>
    <contact_backup>
      <last_name>Ahmad AlGhadi, M.Sc.</last_name>
      <phone>+962796624217</phone>
      <email>ahmed.alghadi@stemcellsarabia.net</email>
    </contact_backup>
    <investigator>
      <last_name>Ahmad Y AlGhadi, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sumaya H Aldajah, M.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marwa E Tapponi, Pharm.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sameh N AlBakheet, B.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahasen Zalloum, B.Sc.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 15, 2020</study_first_submitted>
  <study_first_submitted_qc>March 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 15, 2020</last_update_submitted>
  <last_update_submitted_qc>March 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stem Cells Arabia</investigator_affiliation>
    <investigator_full_name>Adeeb Al Zoubi</investigator_full_name>
    <investigator_title>President, Chief Scientific Officer</investigator_title>
  </responsible_party>
  <keyword>Stem Cells, COVID-19, SARS CoV2, WJ MSCs, Immunomodulation,</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

